0000899243-21-037666.txt : 20210924 0000899243-21-037666.hdr.sgml : 20210924 20210924190015 ACCESSION NUMBER: 0000899243-21-037666 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210801 FILED AS OF DATE: 20210924 DATE AS OF CHANGE: 20210924 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LOVE TED W CENTRAL INDEX KEY: 0001188919 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 211278557 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 400 EAST JAMIE COURT, SUITE 101 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2021-08-01 2021-08-03 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001188919 LOVE TED W C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Common Stock 2021-08-01 4 M 0 29955 A 804266 D Common Stock 2021-08-01 4 F 0 14853 27.33 D 789413 D Common Stock 102000 I By Trust 1 Common Stock 102000 I By Trust 2 Common Stock 102000 I By Trust 3 Common Stock 2500 I By Daughter Common Stock 2500 I By Daughter Restricted Stock Units 2021-08-01 4 M 0 9750 0.00 D Common Stock 9750 9750 D Restricted Stock Units 2021-08-01 4 M 0 11250 0.00 D Common Stock 11250 33750 D Restricted Stock Units 2021-08-01 4 M 0 8955 0.00 D Common Stock 8955 44775 D Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 29,955 shares of Common Stock underlying the Reporting Person's RSUs. The shares of Common Stock underlying the RSUs vested in 8 equal semi-annual installments over 4 years from February 1, 2017. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. This amended Form 4 is being filed solely to attach a Power of Attorney granted by the Reporting Person which was not previously attached. All other information in the original Form 4 remains the same. The original Form 4 was timely filed on August 3, 2021. Exhibit 24 - Power of Attorney /s/ Miguel Carrillo, as Attorney-in-Fact 2021-09-24 EX-24 2 attachment1.htm EX-24 DOCUMENT

                           LIMITED POWER OF ATTORNEY

      The undersigned hereby constitutes and appoints each of Jeffrey Farrow,
Tricia Suvari, Kirstin Arnold, Adam Chinnock and Miguel Carrillo, signing
singly, and with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:

      (1)   execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director of Global Blood Therapeutics, Inc. (the
"Company"), from time to time the following U.S. Securities and Exchange
Commission ("SEC") forms: (i) Form ID, including any attached documents, to
effect the assignment of codes to the undersigned to be used in the transmission
of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement
of Beneficial Ownership of Securities, including any attached documents;  (iii)
Form 4, Statement of Changes in Beneficial Ownership of Securities, including
any attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of
Securities in accordance with Section 16(a) of the Securities Exchange Act of
1934, as amended, and the rules thereunder, including any attached documents;
(v) Schedules 13D and 13G and (vi) amendments of each thereof, in accordance
with the Securities Exchange Act of 1934, as amended, and the rules thereunder,
including any attached documents;

      (2)   do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4
or 5, Schedules 13D and 13G or any amendment(s) thereto, and timely file such
form(s) with the SEC and any securities exchange, national association or
similar authority; and

      (3)   take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

      The undersigned hereby grants to each such attorney-in-fact, acting
singly, full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended.  The undersigned hereby agrees
to indemnify the attorneys-in-fact and the Company from and against any demand,
damage, loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorneys-in-fact.

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.  This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company.  This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an employee of
the Company.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of June 8, 2021.


                                        /s/ Ted W. Love
                                        ------------------------
                                        Ted W. Love